DGAP-Adhoc

Evotec's partner Roche provides initial update from Phase IIb trial in Alzheimer's disease

Evotec AG / Key word(s): Miscellaneous

30.06.2015 20:47

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) was updated today by its partner Roche
(SIX: RO, ROG; OTCQX: RHHBY) on the initial results of the Phase IIb trial
with Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of
Alzheimer's disease ("AD"). In this study, Sembragiline failed to
demonstrate benefit on the primary endpoint (Alzheimer's Disease Assessment
Scale - Cognitive Behaviour Subscale, ADAS-cog-11) after 52 weeks of
treatment. Preliminary safety analyses showed that Sembragiline was well
tolerated with no safety signals identified. Roche has initiated a process
to evaluate all secondary endpoint read-outs on Sembragiline and to
consider all further development options. The Phase IIb study was
undertaken to evaluate the efficacy and safety of Sembragiline in patients
with moderate severity Alzheimer's disease added on background of AD
standard therapy.

Today's news has no impact on Evotec's financial guidance.


Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: [phone]
81-242, [e-mail]


30.06.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------